STUDIES IN THE MEDICAL LITERATURE SINCE THE 1970S HAVE STRONGLY SUGGESTED THAT EICOSAPENTAENOIC ACID (EPA) IS A SIGNIFICANT MODULATOR OF THROMBOXANE AND PROSTAGLANDIN ACTIVITY, PRIMARILY IN ITS ROLE AS A PRECURSOR OF THE 3 CLASS OF THROMBOXANES AND

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$33,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
4988
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Lipid Specialties
21 Tioga Way, Marblehead, MA, 01945
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 DR BARRY SEARS
 PRINCIPAL INVESTIGATOR
 (617) 639-2400
Business Contact
Phone: () -
Research Institution
N/A
Abstract
STUDIES IN THE MEDICAL LITERATURE SINCE THE 1970S HAVE STRONGLY SUGGESTED THAT EICOSAPENTAENOIC ACID (EPA) IS A SIGNIFICANT MODULATOR OF THROMBOXANE AND PROSTAGLANDIN ACTIVITY, PRIMARILY IN ITS ROLE AS A PRECURSOR OF THE 3 CLASS OF THROMBOXANES AND PROSTAGLANDINS. A RECENT 20-YEAR EPIDEMIOLOGICAL STUDY UNCOVERED A STRONG CORRELATION BETWEENINCREASED FISH CONSUMPTION AND DECREASED CARDIOVASCULAR DISEASE MORTALITY IN A DUTCH POPULATION. A DIET CONTAINING GREATER THAN 400MG PER DAY OF EPA GAVE GREATER THAN A 50% REDUCTION IN CARDIOVASCULAR DISEASE MORTALITY, COMPARED WITHA DIET CONTAINING NO FISH OIL. IT APPEARS POSSIBLE FROM THIS AND OTHER STUDIES THAT A RELATIVELY LOW INTAKE OF EPA- FISH OILS ON A CHRONIC BASIS MAY SUBSTANTIALLY REDUCE THE RISK OF CARDIOVASCULAR MORTALITY. LIPID SPECIALTIES HAS RECENTLY PROCESSED A FISH OIL TO CONTAIN 30% EPA WITHOUT HEAVY METAL OR PCB CONTAMINATION. PHASE I RESEARCH WILL FOCUS ON STABILIZING EPA-FISH OILS USING TOCOPHEROLS AND A NEW CLASS OF SEMISYNTHETIC PHOSPHOLIPIDS, THE LIPID X SURFACTANTS. THESE SURFACTANTS ARE UNIQUE IN BEING COMPLETELY MISCIBLE WITH OILS, AND SO WILL SOLUBILIZE THE TOCOPHEROLS. IF THE RESISTANCE TO OXIDATION CAN BE RAISED TO GREATER THAN AN AOM OF 8 HOURS, PHASE II STUDIES WOULD INCLUDE TOXICOLOGY STUDIES OF LIPID X ADMINISTERED ORALLY TOANIMALS, WITH A GOAL OF OBTAINING FDA APPROVAL OF LIPID X AS A FOOD ADDITIVE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government